UNITED STA TES p A TENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www .uspto.gov
`
`APPLICATION NO.
`
`13/910,583
`
`ISSUE DATE
`
`06/10/2014
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`8748657
`
`080618-1255
`
`7133
`
`7590
`22428
`05/21/2014
`FOLEY AND LARDNER LLP
`SUITE 500
`3000 K STREET NW
`WASHINGTON, DC 20007
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`United Therapeutics Corporation, Silver Spring, MD, Assignee (with 37 CFR 1.172 Interest);
`Hitesh Batra, Herndon, VA;
`Sudersan M. Tuladhar, Silver Spring, MD;
`Raju Penmasta, Herndon, VA;
`David A. Walsh, Palmyra, VA;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`1
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`APPLICATION
`NUMBER
`13/910,583
`
`FILING or
`37l(c)DATE
`06/05/2013
`
`GRPART
`UNIT
`1672
`
`FIL FEE REC'D
`1900
`
`22428
`FOLEY AND LARDNER LLP
`SUITE 500
`3000 K STREET NW
`WASHINGTON, DC 20007
`
`Ul\TfED STATES DEPA RTME'IT OF COMMERCE
`United States Patent and Trademark Office
`Adm"'· COMMISSIO'JER FOR PATENTS
`PO Box 1450
`Alexandria, Virgmia 22313-1450
`\VVi\V.USpto.gov
`
`ATTY.DOCKET.NO
`080618-1255
`
`TOT CLAIMS IND CLAIMS
`14
`1
`CONFIRMATION NO. 7133
`CORRECTED FILING RECEIPT
`
`111111111111111111111111]~!l]~~1~~1~~H~ ~1~1~~~1111111111111111111111111
`
`Date Mailed: 05/13/2014
`
`Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination
`in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the
`application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE,
`NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the
`changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit
`any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply
`to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections
`
`lnventor(s)
`
`Applicant( s)
`
`Hitesh Batra, Herndon, VA;
`Sudersan M. Tuladhar, Silver Spring, MD;
`Raju Penmasta, Herndon, VA;
`David A. Walsh, Palmyra, VA;
`
`United Therapeutics Corporation, Silver Spring, MD
`
`Power of Attorney: The patent practitioners associated with Customer Number 22428
`
`Domestic Priority data as claimed by applicant
`This application is a CON of 13/548,446 07/13/2012 PAT 8497393
`which is a CON of 12/334,731 12/15/2008 PAT 8242305
`which claims benefit of 61/014,232 12/17/2007
`
`Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution
`Highway program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
`Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to
`foreign priority. See 37 CFR 1.55 and 1.76.
`
`Permission to Access - A proper Authorization to Permit Access to Application by Participating Offices
`(PTO/SB/39 or its equivalent) has been received by the USPTO.
`
`If Required, Foreign Filing License Granted: 06/24/2013
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 13/910,583
`
`page 1of3
`
`2
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Projected Publication Date: Not Applicable
`
`Non-Publication Request: No
`
`Early Publication Request: No
`Title
`
`PROCESS TO PREPARE TREPROSTINIL
`
`Preliminary Class
`
`562
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`Applicants also are advised that in the case of inventions made in the United States, the Director of the US PTO must
`issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Government hotline at 1-866-999-HAL T (1-866-999-4258).
`
`page 2 of 3
`
`3
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`Select USA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote and facilitate business investment. SelectUSA provides information assistance to the international investor
`community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call
`+ 1-202-482-6800.
`
`page 3 of 3
`
`4
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`UNITED STA IBS p A IBNT AND TRADEMARK OFFICE
`
`UNITED STA TES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`13/910,583
`
`06/05/2013
`
`Hitesh Batra
`
`080618-1255
`
`7133
`
`22428
`7590
`05/12/2014
`FOLEY AND LARDNER LLP
`SUIIB 500
`3000 K STREET NW
`WASHINGTON, DC 20007
`
`EXAMINER
`
`VALENROD,YEVGENY
`
`ART UNIT
`
`PAPER NUMBER
`
`1672
`
`MAILDATE
`
`DELIVERY MODE
`
`05/12/2014
`
`PAPER
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`PTOL-90A (Rev. 04/07)
`
`5
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`supplemental
`Notice of Allowability
`
`Application No.
`13/910,583
`Examiner
`YEVGENY VALEN ROD
`
`Applicant(s)
`BATRA ET AL.
`AIA (First Inventor to
`Art Unit
`File) Status
`1672
`No
`
`-- The MAILING DA TE of this communication appears on the cover sheet with the correspondence address-(cid:173)
`All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included
`herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS
`NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
`of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
`
`1. [gl This communication is responsive to RUSH dated 4130114.
`DA declaration(s)/affidavit(s) under 37 CFR 1.130(b) was/were filed on ___ .
`2. D An election was made by the applicant in response to a restriction requirement set forth during the interview on __ ; the restriction
`requirement and election have been incorporated into this action.
`
`3. [gl The allowed claim(s) is/are LJ. As a result of the allowed claim(s), you may be eligible to benefit from the Patent Prosecution
`Highway program at a participating intellectual property office for the corresponding application. For more information, please see
`~1tl;Q://v1rNw.us2to.gov/gatents/init events/Qgh/indexjs.Q or send an inquiry to PPHfeedback@uS(Qto.aov .
`4. D Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
`Certified copies:
`*c) D None of the:
`a) D All
`b) D Some
`1. D Certified copies of the priority documents have been received.
`2. D Certified copies of the priority documents have been received in Application No. __ .
`3. D Copies of the certified copies of the priority documents have been received in this national stage application from the
`International Bureau (PCT Rule 17.2(a)).
`* Certified copies not received: __ .
`
`Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements
`noted below. Failure to timely comply will result in ABANDONMENT of this application.
`THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
`5. D CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
`D including changes required by the attached Examiner's Amendment I Comment or in the Office action of
`Paper No./Mail Date __ .
`Identifying indicia such as the application number {see 37 CFR 1.84{c)) should be written on the drawings in the front {not the back) of
`each sheet. Replacement sheet{s) should be labeled as such in the header according to 37 CFR 1.121 {d).
`6. 0 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
`attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
`
`Attachment(s)
`1. D Notice of References Cited (PT0-892)
`2. D Information Disclosure Statements (PTO/SB/08),
`Paper No./Mail Date __
`3. D Examiner's Comment Regarding Requirement for Deposit
`of Biological Material
`4. [gl Interview Summary (PT0-413),
`Paper No./Mail Date 518114.
`
`/YEVGENY VALEN ROD/
`Primary Examiner, Art Unit 1672
`
`5. [gl Examiner's Amendment/Comment
`6. D Examiner's Statement of Reasons for Allowance
`7. D Other __ .
`
`U.S. Patent and Trademark Office
`PTOL-37 (Rev. 08-13)
`
`Notice of Allowability
`
`Part of Paper No./Mail Date 20140508
`
`6
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Application/Control Number: 13/910,583
`Art Unit: 1672
`
`Page 2
`
`The present application is being examined under the pre-AIA first to invent
`
`provisions.
`
`EXAMINER'S AMENDMENT
`
`An examiner's amendment to the record appears below. Should the changes
`
`and/or additions be unacceptable to applicant, an amendment may be filed as provided
`
`by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be
`
`submitted no later than the payment of the issue fee.
`
`Authorization for this examiner's amendment was given in a telephone interview
`
`with Alexey V. Saprigin on 5/8/14.
`
`The application has been amended as follows:
`
`The title of the application has been amended to read: "Process to Prepare
`
`Treprostinil".
`
`Any inquiry concerning this communication or earlier communications from the
`
`examiner should be directed to Yevgeny Valenrod whose telephone number is 571-272-
`
`9049. The examiner can normally be reached on 8:30am-5:00pm M-F.
`
`If attempts to reach the examiner by telephone are unsuccessful, the examiner's
`
`supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number
`
`for the organization where this application or proceeding is assigned is 571-273-8300.
`
`7
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Application/Control Number: 13/910,583
`Art Unit: 1672
`
`Page 3
`
`Information regarding the status of an application may be obtained from the
`
`Patent Application Information Retrieval (PAIR) system. Status information for
`
`published applications may be obtained from either Private PAIR or Public PAIR.
`
`Status information for unpublished applications is available through Private PAIR only.
`
`For more information about the PAIR system, see http://pair-direct.uspto.gov. Should
`
`you have questions on access to the Private PAIR system, contact the Electronic
`
`Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a
`
`USPTO Customer Service Representative or access to the automated information
`
`system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
`
`/YEVGENY VALENROD/
`Primary Examiner, Art Unit 1672
`
`8
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Examiner-Initiated Interview Summary
`
`Application No.
`
`Applicant(s)
`
`13/910,583
`
`Examiner
`
`BATRA ET AL.
`
`Art Unit
`
`YEVGENY VALEN ROD
`
`1672
`
`All participants (applicant, applicant's representative, PTO personnel):
`
`(1) YEVGENY VALENROD.
`
`(2) Alexev V Sapriqin.
`
`(3) __ .
`
`(4) __ .
`
`Type:
`
`Date of Interview: 08 Mav 2014.
`IZI Telephonic 0 Video Conference
`0 Personal [copy given to: 0 applicant
`Exhibit shown or demonstration conducted: 0 Yes
`If Yes, brief description: __ .
`
`0 applicant's representative]
`IZI No.
`
`Issues Discussed 0101 0112 0102 0103 IZ!Others
`(For each of the checked box( es) above, please describe below the issue and detailed description of the discussion)
`
`Claim(s) discussed: none.
`
`Identification of prior art discussed: none.
`
`Substance of Interview
`(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a
`reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc ... )
`
`A proposed amendment to the title of the application was discussed and agreed upon .
`
`Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.
`
`Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of
`the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the
`general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the
`general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.
`0 Attachment
`/YEVGENY VALENROD/
`Primary Examiner, Art Unit 1672
`
`U.S. Patent and Trademark Office
`PTOL-4138 (Rev. 8/11/2010)
`
`Interview Summary
`
`PaperNo.20140508
`
`9
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`PART B- FEE(S) TRANSMITTAL
`Complete and send this form, together with applicable fee(s), to: MBil Mail StoP. ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`( 571 )-273-2885
`
`or.Ell
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where
`appropriate. All further correspondence including th~ Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless correl'led below or dire<:Led otherwise in Bkx:k I, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (N:Xe: Use Block I for any change of address)
`
`22428
`7590
`04/1512014
`FOLEY AND LARDNER LLP
`SUITES()()
`3000 K STREET NW
`WASHINGTON, DC 20007
`
`Note: A certificate of mailing can only be used for domestic mailings of the
`Fee(s) TransmiuaL This l:ertilicate cannot be used for any other accompanying
`papers. Each additional paper, such as an assi$nment or formal drawing, must
`have its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`States Postal S'ervice with sufficient postage for first class mail in an envelor.e
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`
`~~·->1
`
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFJRMATION NO.
`
`D/910,583
`
`0610512013
`
`Hitesh Batra
`
`080618-1255
`
`7133
`
`TI'ILE OF INVENTION: PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
`
`APPLN. TYPE
`
`ENITTY STATI.JS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`DATE DUE
`
`07115/2014
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBC1..ASS
`
`VALENROD,YEVGENY
`
`1672
`
`562-466000
`
`I. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`0 Change of corresr,~mdence address (or Chllnge of Correspondence
`Address form PTO/SB/122) attached.
`0 "Fee Address" indication (or "l'ee Address" Indication form
`PTO/SB/47; Rev OJ-02 or more recent) attached. Use of a Customer
`Number is required.
`
`2. For printing on the patent front page, list
`(I) The names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`(2) The name of a single firm (having as a member a
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`listed, no name will be printed.
`
`l Foley & Lardner L.=L=-P __
`
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for
`recordation as set forth in 37 CPR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY!
`
`Silver Spring, MD
`United Therapeutics Corporation
`Please check the appropriate assignee category or categories (will not be printed on the patent) : 0 Individual Ga Corporation or other private group entity 0 Government
`
`4a The following fee(s) are submitted:
`i) Issue Fee
`0 Publication Fee (No small entity discount permitted)
`0 Advance Order - #of Copies _________ _
`
`5. Change io Entity Status (from status indicated above)
`0 Applicant certifying micro entity status. See 37 CFR l.29
`0 Applicant asserting small entity status. See 37 CFR 1.27
`0 Applicant changing to regular undiscounted fee status.
`
`4b. Payment ofFee(s): (Please first reapply any previously paid issue fee shown above)
`0 A check is enclosed.
`~ Payment by credit card. Form PT0-2038 is attached.
`:ID The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any
`overpayment, to Deposit Account Number J 9 074 J
`(enclose an extra copy of this form).
`
`NQIB;_ Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and !SB), issue
`reepayment in the micro entity amount will not be accepted at the risk of application abandonment.
`NQIB;_ If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`NQJ1t Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable .
`
`. 33. See 37 CFR 1.4 for si nature re uirements and certifications.
`
`Authori1.ed Signat
`
`Date _____ _
`Registration No. ~_,2_6_4---,r----,,-F'"--""--i~
`
`Page 2 of3
`
`PTOL-85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB 0651-0033
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`10
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`13910583
`
`05-Jun-2013
`
`Title of Invention:
`
`PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN
`REMODULIN®
`
`First Named Inventor/Applicant Name:
`
`Hitesh Batra
`
`Filer:
`
`Alexey V. Saprigin/Karen Walker
`
`Attorney Docket Number:
`
`08061 8-1 255
`
`Filed as Large Entity
`
`Utility under 35 USC 111 (a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`Utility Appl Issue Fee
`
`1501
`
`1
`
`960
`
`960
`
`Extension-of-Time:
`
`11
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USO($)
`
`Miscellaneous:
`
`Total in USO($)
`
`960
`
`12
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`18815666
`
`13910583
`
`International Application Number:
`
`Confirmation Number:
`
`7133
`
`Title of Invention:
`
`PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN
`REMODULIN®
`
`First Named Inventor/Applicant Name:
`
`Hitesh Batra
`
`Customer Number:
`
`22428
`
`Filer:
`
`Alexey V. Saprigin/Karen Walker
`
`Filer Authorized By:
`
`Alexey V. Saprigin
`
`Attorney Docket Number:
`
`08061 8-1 255
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`21-APR-2014
`
`05-JUN-2013
`
`15:59:31
`
`Application Type:
`
`Utility under 35 USC 111 (a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`RAM confirmation Number
`
`yes
`
`Credit Card
`
`$960
`
`2370
`
`Deposit Account
`
`Authorized User
`
`File Listing:
`Document I
`Number
`
`Document Description
`
`File Name
`
`I
`
`File Size( Bytes)/ I Multi I Pages
`(if appl.)
`Message Digest
`Part /.zip
`
`I
`
`13
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`1
`
`Issue Fee Payment (PT0-85B)
`
`IFTM.pdf
`
`no
`
`1
`
`92338
`
`Warnings:
`
`Information:
`
`f48df2630e8b6713d595c50d608526aa865
`88a2d
`
`30694
`
`2
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`91800765ad9b97b87ae4 7199e49ab359bb
`b1e3cd
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes)
`
`123032
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New A~~lications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International A~~lication under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International A~~lication Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 181 O), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/R0/1 OS) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`14
`
`UT Ex. 2010
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`UNITED STA IBS p A IBNT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`22428
`7590
`04/15/2014
`FOLEY AND LARDNER LLP
`SUITE 500
`3000 K STREET NW
`WASHINGTON, DC 20007
`
`EXAMINER
`
`VALENROD,YEVGENY
`
`ART UNIT
`
`PAPER NUMBER
`
`1672
`
`DATE MAILED: 04/15/2014
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`13/910,583
`
`06/05/2013
`
`Hitesh Batra
`
`080618-1255
`
`7133
`
`TITLE OF INVENTION: PROCESS TO PREP ARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATEDUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`07/15/2014
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that
`entity status still applies.
`If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled
`"Change in Entity Status (from status indicated above)".
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity
`fees.
`
`IL PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalent of Part B.
`
`III. All communications regarding this application must give the application